{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,16]],"date-time":"2026-05-16T13:51:54Z","timestamp":1778939514355,"version":"3.51.4"},"reference-count":36,"publisher":"Georg Thieme Verlag KG","issue":"10","license":[{"start":{"date-parts":[[2024,6,11]],"date-time":"2024-06-11T00:00:00Z","timestamp":1718064000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Thromb Haemost"],"published-print":{"date-parts":[[2024,10]]},"abstract":"<jats:p>\n            Background\u2003Fidanacogene elaparvovec, an adeno-associated virus-based gene therapy vector expressing the high-activity factor IX (FIX) variant FIX-R338L, is in development for hemophilia B. One-stage clotting (OS) assays and chromogenic substrate (CS) assays are commonly used to measure FIX-R338L variant activity. Data from ongoing trials suggest FIX activity varies between different OS and CS assays.<\/jats:p><jats:p>\n            Material and Methods\u2003To better understand FIX-R338L activity in clinical samples, an international multisite field study was conducted across a central laboratory and 18 local laboratories, using standard protocols, reagents, and instrumentation, with individual participant samples from a phase 1\/2a study of fidanacogene elaparvovec.<\/jats:p><jats:p>\n            Results\u2003Unlike the wild-type FIX control, FIX-R338L activity was higher with the OS silica-based assay versus OS ellagic acid\u2013based and CS assays. Variation in FIX activity was greater at the lowest activity levels. Activated FIX (FIXa) in plasma could result in higher OS assay activity or increased thrombin generation, which could overestimate FIX activity. However, FIXa was not detected in the participant samples, indicating that it was not contributing to the OS assay differences. Since individuals on gene therapy may receive exogenous replacement FIX products, replacement products were spiked into patient plasma samples to target a therapeutic concentration. Exogenous FIX was additive to endogenous FIX-R338L, with no interference from FIX-R338L.<\/jats:p><jats:p>\n            Conclusion\u2003These results demonstrate FIX-R338L activity can be measured with OS and CS assays in clinical laboratories and provide insight into assay variability when measuring FIX with endogenously produced FIX-R338L. The findings may help establish best practices for measuring FIX-R338L activity (Clinicaltrials.gov identifier: NCT02484092).<\/jats:p>","DOI":"10.1055\/s-0044-1787734","type":"journal-article","created":{"date-parts":[[2024,6,12]],"date-time":"2024-06-12T05:02:06Z","timestamp":1718168526000},"page":"912-921","source":"Crossref","is-referenced-by-count":7,"title":["Field Study and Correlative Studies of Factor IX Variant FIX-R338L in Participants Treated with Fidanacogene Elaparvovec"],"prefix":"10.1055","volume":"124","author":[{"given":"Debra D.","family":"Pittman","sequence":"additional","affiliation":[{"name":"Rare Disease Research Unit, Pfizer Inc., Cambridge, Massachusetts, United States"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Charles","family":"Carrieri","sequence":"additional","affiliation":[{"name":"Pfizer Inc., New York, New York, United States"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Holly","family":"Soares","sequence":"additional","affiliation":[{"name":"Pfizer Inc., New York, New York, United States"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John","family":"McKay","sequence":"additional","affiliation":[{"name":"Pfizer Inc., Groton, Connecticut, United States"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Charles Y.","family":"Tan","sequence":"additional","affiliation":[{"name":"Pfizer Inc., Groton, Connecticut, United States"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John Z.","family":"Liang","sequence":"additional","affiliation":[{"name":"Pfizer Inc., New York, New York, United States"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Swapnil","family":"Rakhe","sequence":"additional","affiliation":[{"name":"Rare Disease Research Unit, Pfizer Inc., Cambridge, Massachusetts, United States"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jean-Claude","family":"Marshall","sequence":"additional","affiliation":[{"name":"Pfizer Inc., Groton, Connecticut, United States"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John E.","family":"Murphy","sequence":"additional","affiliation":[{"name":"Rare Disease Research Unit, Pfizer Inc., Cambridge, Massachusetts, United States"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Puneet","family":"Gaitonde","sequence":"additional","affiliation":[{"name":"Pfizer Inc., Cambridge, Massachusetts, United States"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jeremy","family":"Rupon","sequence":"additional","affiliation":[{"name":"Pfizer Inc., Collegeville, Pennsylvania, United States"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"194","published-online":{"date-parts":[[2024,6,11]]},"reference":[{"key":"ref1","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/hae.14046","article-title":"WFH Guidelines for the Management of Hemophilia, 3rd edition","volume":"26","author":"A Srivastava","year":"2020","journal-title":"Haemophilia"},{"issue":"04","key":"ref2","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1111\/j.1365-2516.2001.00534.x","article-title":"Barriers to compliance with prophylaxis therapy in haemophilia","volume":"7","author":"M R Hacker","year":"2001","journal-title":"Haemophilia"},{"issue":"03","key":"ref3","doi-asserted-by":"crossref","first-page":"e140","DOI":"10.1111\/j.1365-2516.2012.02770.x","article-title":"Treatment trends for haemophilia A and haemophilia B in the United States: results from the 2010 practice patterns survey","volume":"18","author":"S Zappa","year":"2012","journal-title":"Haemophilia"},{"issue":"05","key":"ref4","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1111\/j.1365-2516.2008.01843.x","article-title":"A survey of adherence to haemophilia therapy in six European countries: results and recommendations","volume":"14","author":"P De Moerloose","year":"2008","journal-title":"Haemophilia"},{"issue":"02","key":"ref5","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1111\/j.1365-2516.2006.01172.x","article-title":"Adherence to prophylactic infusions of factor VIII or factor IX for haemophilia","volume":"12","author":"C D Thornburg","year":"2006","journal-title":"Haemophilia"},{"issue":"01","key":"ref6","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1111\/j.1365-2516.2006.01189.x","article-title":"Practice patterns in haemophilia A therapy \u2013 global progress towards optimal care","volume":"12","author":"S Geraghty","year":"2006","journal-title":"Haemophilia"},{"issue":"S 01","key":"ref7","doi-asserted-by":"crossref","first-page":"3347","DOI":"10.1182\/blood-2019-124091","article-title":"Efficacy and safety in 15 hemophilia b patients treated with the AAV gene therapy vector fidanacogene elaparvovec and followed for at least 1 year","volume":"134","author":"L A George","year":"2019","journal-title":"Blood"},{"issue":"05","key":"ref8","doi-asserted-by":"crossref","first-page":"1212","DOI":"10.1111\/jth.15281","article-title":"Factor IX assay discrepancies in the setting of liver gene therapy using a hyperfunctional variant factor IX-Padua","volume":"19","author":"M M Robinson","year":"2021","journal-title":"J Thromb Haemost"},{"issue":"17","key":"ref9","doi-asserted-by":"crossref","first-page":"1671","DOI":"10.1056\/NEJMoa0904377","article-title":"X-linked thrombophilia with a mutant factor IX (factor IX Padua)","volume":"361","author":"P Simioni","year":"2009","journal-title":"N Engl J Med"},{"issue":"23","key":"ref10","doi-asserted-by":"crossref","first-page":"2215","DOI":"10.1056\/NEJMoa1708538","article-title":"Hemophilia B gene therapy with a high-specific-activity factor IX variant","volume":"377","author":"L A George","year":"2017","journal-title":"N Engl J Med"},{"key":"ref11","doi-asserted-by":"crossref","first-page":"3975","DOI":"10.1182\/blood-2021-150541","article-title":"Follow-up of more than 5 years in a cohort of patients with hemophilia B treated with fidanacogene elaparvovec adeno-associated virus gene therapy","volume":"138","author":"B J Samelson-Jones","year":"2021","journal-title":"Blood"},{"issue":"06","key":"ref12","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1111\/ijlh.12877","article-title":"Advantages, disadvantages and optimization of one-stage and chromogenic factor activity assays in haemophilia A and B","volume":"40","author":"D M Adcock","year":"2018","journal-title":"Int J Lab Hematol"},{"issue":"03","key":"ref13","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1055\/s-0037-1598058","article-title":"Factor activity assays for monitoring extended half-life FVIII and factor IX replacement therapies","volume":"43","author":"S Kitchen","year":"2017","journal-title":"Semin Thromb Hemost"},{"issue":"04","key":"ref14","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1055\/a-1665-6232","article-title":"An update on laboratory diagnostics in haemophilia A and B","volume":"42","author":"J M\u00fcller","year":"2022","journal-title":"Hamostaseologie"},{"issue":"04","key":"ref15","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1111\/hae.12639","article-title":"Current laboratory practices in the diagnosis and management of haemophilia: a global assessment","volume":"21","author":"S Kitchen","year":"2015","journal-title":"Haemophilia"},{"issue":"05","key":"ref16","first-page":"932","article-title":"Comparative field study: impact of laboratory assay variability on the assessment of recombinant factor IX Fc fusion protein (rFIXFc) activity","volume":"112","author":"J M Sommer","year":"2014","journal-title":"Thromb Haemost"},{"issue":"06","key":"ref17","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1111\/hae.12449","article-title":"Recombinant factor IX: discrepancies between one-stage clotting and chromogenic assays","volume":"20","author":"H V Wilmot","year":"2014","journal-title":"Haemophilia"},{"issue":"03","key":"ref18","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1182\/bloodadvances.2022007435","article-title":"Differences in wild-type- and R338L-tenase complex formation are at the root of R338L-factor IX assay discrepancies","volume":"7","author":"J H Foley","year":"2023","journal-title":"Blood Adv"},{"key":"ref19","first-page":"197","article-title":"Assessment of factor IX Padua activity with a one-stage clotting method and with FXIa- and tissue factor\/FVIIa- based chromogenic methods","volume":"3","author":"S Rosen","year":"2019","journal-title":"Res Pract Thromb Haemost"},{"issue":"01","key":"ref21","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1111\/jth.14332","article-title":"Performance of a recombinant fusion protein linking coagulation factor IX with recombinant albumin in one-stage clotting assays","volume":"17","author":"C Horn","year":"2019","journal-title":"J Thromb Haemost"},{"issue":"07","key":"ref22","doi-asserted-by":"crossref","first-page":"1428","DOI":"10.1111\/jth.13348","article-title":"Measuring factor IX activity of nonacog beta pegol with commercially available one-stage clotting and chromogenic assay kits: a two-center study","volume":"14","author":"A E Bowyer","year":"2016","journal-title":"J Thromb Haemost"},{"issue":"10","key":"ref23","doi-asserted-by":"crossref","first-page":"1901","DOI":"10.1111\/jth.13787","article-title":"Qualification of a select one-stage activated partial thromboplastin time-based clotting assay and two chromogenic assays for the post-administration monitoring of nonacog beta pegol","volume":"15","author":"S Tiefenbacher","year":"2017","journal-title":"J Thromb Haemost"},{"issue":"01","key":"ref24","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1111\/hae.13907","article-title":"Laboratory measurement of factor replacement therapies in the treatment of congenital haemophilia: a United Kingdom Haemophilia Centre Doctors' Organisation guideline","volume":"26","author":"E Gray","year":"2020","journal-title":"Haemophilia"},{"issue":"06","key":"ref25","doi-asserted-by":"crossref","first-page":"1696","DOI":"10.1172\/JCI111377","article-title":"Regulation of factor IXa in vitro in human and mouse plasma and in vivo in the mouse. Role of the endothelium and the plasma proteinase inhibitors","volume":"73","author":"H E Fuchs","year":"1984","journal-title":"J Clin Invest"},{"key":"ref26","doi-asserted-by":"crossref","first-page":"7678901","DOI":"10.1155\/2016\/7678901","article-title":"Characterization of IXINITY(R) (trenonacog alfa), a recombinant factor IX with primary sequence corresponding to the threonine-148 polymorph","volume":"2016","author":"D M Monroe","year":"2016","journal-title":"Adv Hematol"},{"issue":"04","key":"ref27","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1182\/blood.V76.4.731.731","article-title":"Factor IX is activated in vivo by the tissue factor mechanism","volume":"76","author":"K A Bauer","year":"1990","journal-title":"Blood"},{"issue":"22","key":"ref28","doi-asserted-by":"crossref","first-page":"22875","DOI":"10.1074\/jbc.M400531200","article-title":"The significance of circulating factor IXa in blood","volume":"279","author":"S Butenas","year":"2004","journal-title":"J Biol Chem"},{"issue":"03","key":"ref29","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1056\/NEJMoa2119913","article-title":"phase 1-2 trial of AAVS3 gene therapy in patients with hemophilia B","volume":"387","author":"P Chowdary","year":"2022","journal-title":"N Engl J Med"},{"issue":"21","key":"ref30","doi-asserted-by":"crossref","first-page":"3241","DOI":"10.1182\/bloodadvances.2019000811","article-title":"Etranacogene dezaparvovec (AMT-061 phase 2b): normal\/near normal FIX activity and bleed cessation in hemophilia B","volume":"3","author":"A Von Drygalski","year":"2019","journal-title":"Blood Adv"},{"issue":"08","key":"ref31","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1056\/NEJMoa2211644","article-title":"gene therapy with etranacogene dezaparvovec for hemophilia B","volume":"388","author":"S W Pipe","year":"2023","journal-title":"N Engl J Med"},{"issue":"05","key":"ref33","doi-asserted-by":"crossref","first-page":"e363","DOI":"10.1111\/hae.13556","article-title":"Potency estimates for recombinant factor IX in the one-stage clotting assay are influenced by more than just the choice of activated partial thromboplastin time reagent","volume":"24","author":"H V Wilmot","year":"2018","journal-title":"Haemophilia"},{"issue":"S 06","key":"ref34","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1111\/j.1365-2516.2010.02300.x","article-title":"Insights from factor IX activation studies with chromogenic assays: implications of disparate product results","volume":"16","author":"T W Barrowcliffe","year":"2010","journal-title":"Haemophilia"},{"issue":"07","key":"ref35","doi-asserted-by":"crossref","first-page":"1420","DOI":"10.1111\/jth.13359","article-title":"Overestimation of N-glycoPEGylated factor IX activity in a one-stage factor IX clotting assay owing to silica-mediated premature conversion to activated factor IX","volume":"14","author":"P Ros\u00e9n","year":"2016","journal-title":"J Thromb Haemost"},{"issue":"02","key":"ref36","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1111\/hae.13915","article-title":"FIX potency of rFIX-Albumin fusion protein is underestimated by one-stage methods using silica-based APTT reagents","volume":"26","author":"S Ros\u00e9n","year":"2020","journal-title":"Haemophilia"},{"issue":"07","key":"ref38","doi-asserted-by":"crossref","first-page":"1532","DOI":"10.1111\/j.1538-7836.2010.03899.x","article-title":"Coagulation procofactor activation by factor XIa","volume":"8","author":"M F Whelihan","year":"2010","journal-title":"J Thromb Haemost"},{"issue":"14","key":"ref39","doi-asserted-by":"crossref","first-page":"e128683","DOI":"10.1172\/jci.insight.128683","article-title":"Hyperactivity of factor IX Padua (R338L) depends on factor VIIIa cofactor activity","volume":"5","author":"B J Samelson-Jones","year":"2019","journal-title":"JCI Insight"}],"container-title":["Thrombosis and Haemostasis"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.thieme-connect.de\/products\/ejournals\/pdf\/10.1055\/s-0044-1787734.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,5]],"date-time":"2024-11-05T12:17:22Z","timestamp":1730809042000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.thieme-connect.de\/DOI\/DOI?10.1055\/s-0044-1787734"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6,11]]},"references-count":36,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2024,9,27]]},"published-print":{"date-parts":[[2024,10]]}},"URL":"https:\/\/doi.org\/10.1055\/s-0044-1787734","archive":["Portico","CLOCKSS"],"relation":{},"ISSN":["0340-6245","2567-689X"],"issn-type":[{"value":"0340-6245","type":"print"},{"value":"2567-689X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,6,11]]}}}